A report released today by Zacks Investment Research about Neos Therapeutics Inc (NASDAQ:NEOS) raises the target price to $7.75
- Updated: October 13, 2016
In a report announced on 10/13/2016 Zacks Investment Research bumped up the target of Neos Therapeutics Inc (NASDAQ:NEOS) to $7.75 stating a potential upside of 0.15%.
Just yesterday Neos Therapeutics Inc (NASDAQ:NEOS) traded 2.96% higher at $6.76. Neos Therapeutics Inc’s 50-day moving average is $7.05 and its 200-day moving average is $8.66. The last stock close price is down -19.59% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 114,284 shares of the stock were exchanged, down from an average trading volume of 136,805
See Chart Below
Neos Therapeutics Inc has a with a one year low of $6.33 and a one year high of $19.29 Neos Therapeutics Inc’s market capitalization is currently $0.
A total of 4 firms have reported on Neos Therapeutics Inc. zero equity analysts rating the company a strong buy, zero brokerages rating the stock a buy, 0 brokers rating the stock a hold, 0 equity analysts rating the company a underperform, and finally 0 firms rating the stock a sell with a one year target of $22.50.
More About Neos Therapeutics Inc (NASDAQ:NEOS)
Neos Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD). Its product candidates are extended-release (XR), medications in patient-friendly, orally disintegrating tablets (ODT) or liquid suspension dosage forms. Its branded product and product candidates incorporate over two of the prescribed medications for the treatment of ADHD, methylphenidate and amphetamine. Its modified-release drug delivery platform has enabled it to create extended-release ODT and liquid suspension dosage forms of the medications. It focuses on developing Adzenys XR-ODT, Cotempla XR-ODT and NT-0201.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.